Gufic Biosciences Ltd (BOM:509079)

Q4 2025 Gufic Biosciences Ltd Earnings Call Transcript

Jun 2, 2025 / 11:00 AM GMT

Release Date Price: ₹367.1 (-6.08%)

Transcript

Key Points

Positve

Gufic Biosciences Ltd (BOM:509079) has successfully shifted its sales teams to focus on hospitals with high prescribing potential, enhancing relationships in critical care settings.
The company conducted over 125 engagements reaching 1,500 consultants on antimicrobial stewardship and sepsis control, strengthening its market presence.
Gufic Biosciences Ltd launched Elin and IVIG in phases, using market surveys to guide broader rollouts, reinforcing its science-first image.
The company holds top positions in antifungals and has expanded its neuro care division, increasing its market share by 10% year-on-year.
Gufic Biosciences Ltd has signed a landmark distribution agreement covering 17 Latin countries, expanding its international market reach.

Negative

The company reported a decline in EBITDA and profit margins due to increased fixed costs from the Indore facility, impacting overall profitability.
Gufic Biosciences Ltd's revenue remained flat year-on-year, with significant price erosion in key products affecting revenue growth.
The Indore facility is absorbing higher fixed costs, including salaries, utilities, depreciation, and interest, which will continue to pressure margins for the next few quarters.
Despite efforts, the company faces challenges in scaling up its botulinum toxin market share due to limited insurance coverage for therapeutic uses.
The company anticipates that the Indore facility will only achieve EBITDA break-even in FY 2026, with full profitability expected by FY 2027.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

GUFI.NS - Gufic Biosciences Ltd
Q4 2025 Gufic Biosciences Ltd Earnings Call
Jun 02, 2025 / 11:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Q4 and F 525 earnings conference call of QI Biosciences Limited.

As a reminder, all participant lines will be in the less mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing the star, then 0 on your touchtone phone. Please note that this conference is being recorded.

I now have the conference over to Miss Aisha, company secretary Efik by Sciences Limited.

Thank you and over to you, ma'am.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.